"Data presented at AHA signifies the potential of this technology as a clinically viable non-invasive option for hemodynamic-guided heart failure management. We’re excited to move one step closer towards enabling a truly proactive monitoring solution for heart failure patients across the globe.” - Amit Gupta, co-founder and CEO Our Late-Breaking Science at #AHA24 is making news! Explore the findings that detail the performance of our AI-driven non-invasive technology. Read more here:?https://lnkd.in/gb9z7aci #AHAChicago #Cardiosense #CardiacInnovation #NonInvasiveCare #AIinHealthcare With Liviu Klein, Omer Inan, Amit Gupta, Andrew Carek, Venu Ganti, and Arezou Azar, PhD - PMP, CSM
Cardiosense
医院和医疗保健
Chicago，Illinois 2,772 位关注者
Leveraging high-fidelity physiological waveforms to unlock AI-Driven insights in cardiac function.
关于我们
Contact: [email protected] Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI to develop predictive biomarkers for pre-symptomatic disease detection and enable personalized therapy.
- 网站
-
https://www.cardiosense.com
Cardiosense的外部链接
- 所属行业
- 医院和医疗保健
- 规模
- 11-50 人
- 总部
- Chicago，Illinois
- 类型
- 私人持股
地点
-
主要
获取路线
1375 W Fulton St
Suite 650
US，Illinois，Chicago，60607
Cardiosense员工
动态
-
Cardiosense转发了
Cardiovascular disease (CVD) is responsible for over a third of all women's deaths annually—that's more than all cancers combined. Despite this, CVD remains under-diagnosed, under-treated, and understudied in women. Closing this gap in care is crucial. We're thrilled to welcome Cross-Border Impact Ventures to our investor syndicate. Together, we're committed to confronting this critical healthcare need. #WomensHealth #CardiovascularHealth #CVD #HeartHealth #HealthTech?
In honor of Heart Awareness Month and International Women's Day, Cross-Border Impact Ventures is proud to welcome the 9th company to our portfolio, Cardiosense! Cardiosense is combining non-invasive physiological sensors and artificial intelligence for the detection, prediction, and management of cardiovascular disease. The company’s first product is called CardioTag, a wearable multi-sensor device, that together with its SenseHF algorithm, can noninvasively measure pulmonary capillary wedge pressure (PCWP), a leading indicator of escalating congestive heart failure and decompensation. Future use cases of CardioTag can be extended to preeclampsia and arterial blood pressure. We see that Cardiosense can have a huge impact for women's health globally and here is why: - Heart disease is the #1 killer of women - A subpopulation of heart failure called HFpEF disproportionately impacts women - Peripartum cardiomyopathy (heart failure postpartum) directly impacts women - Women who experience premature menopause (before age 40) have a significantly higher risk of developing heart failure and atrial fibrillation - Preeclampsia affects about 2-8% of pregnancies worldwide and is a leading cause of maternal and infant morbidity and mortality. Black women are at a higher risk of developing preeclampsia. We are thrilled to work with Amit Gupta (CEO, Co-founder), Omer Inan (CSO, Co-founder) and the entire Cardiosense team and partner with such a strong syndicate of investors including Hatteras Venture Partners, Broadview Ventures Inc, Laerdal Million Lives Fund, and OSF Ventures among others. Such a huge win for women's cardiovascular health! #cardiosense #womenshealth #Healthtech #heartawareness #heartmonth
-
Cardiovascular disease (CVD) is responsible for over a third of all women's deaths annually—that's more than all cancers combined. Despite this, CVD remains under-diagnosed, under-treated, and understudied in women. Closing this gap in care is crucial. We're thrilled to welcome Cross-Border Impact Ventures to our investor syndicate. Together, we're committed to confronting this critical healthcare need. #WomensHealth #CardiovascularHealth #CVD #HeartHealth #HealthTech?
In honor of Heart Awareness Month and International Women's Day, Cross-Border Impact Ventures is proud to welcome the 9th company to our portfolio, Cardiosense! Cardiosense is combining non-invasive physiological sensors and artificial intelligence for the detection, prediction, and management of cardiovascular disease. The company’s first product is called CardioTag, a wearable multi-sensor device, that together with its SenseHF algorithm, can noninvasively measure pulmonary capillary wedge pressure (PCWP), a leading indicator of escalating congestive heart failure and decompensation. Future use cases of CardioTag can be extended to preeclampsia and arterial blood pressure. We see that Cardiosense can have a huge impact for women's health globally and here is why: - Heart disease is the #1 killer of women - A subpopulation of heart failure called HFpEF disproportionately impacts women - Peripartum cardiomyopathy (heart failure postpartum) directly impacts women - Women who experience premature menopause (before age 40) have a significantly higher risk of developing heart failure and atrial fibrillation - Preeclampsia affects about 2-8% of pregnancies worldwide and is a leading cause of maternal and infant morbidity and mortality. Black women are at a higher risk of developing preeclampsia. We are thrilled to work with Amit Gupta (CEO, Co-founder), Omer Inan (CSO, Co-founder) and the entire Cardiosense team and partner with such a strong syndicate of investors including Hatteras Venture Partners, Broadview Ventures Inc, Laerdal Million Lives Fund, and OSF Ventures among others. Such a huge win for women's cardiovascular health! #cardiosense #womenshealth #Healthtech #heartawareness #heartmonth
-
Our mission to transform cardiac disease management using noninvasive, multi-modal sensors and AI takes our CEO Amit Gupta to MedTech World Dubai. If you’re attending and are interested in joining the fight against preventable cardiac disease, connect with Amit. #MedTechWorldDubai2025 #HeartHealth?
-
-
Heart failure disproportionately impacts Medicare beneficiaries—a burden that is expected to grow over the next decade. Developing healthcare solutions tailored to the unique needs of an aging population is more critical than ever. Visit our website to learn more about our approach to heart failure management: cardiosense.com #HFWeek2025
-
-
Hospital stays and readmissions account for a majority of these costs. Solutions that reduce these events will be crucial in improving patient outcomes while easing the financial strain on our healthcare system. Visit our website to learn more about our approach to heart failure management: cardiosense.com #HFWeek2025
-
-
Heart failure affects nearly 7 million Americans and that number continues to climb. There is a critical need for early screening and targeted preventive measures to help reduce the growing burden on our healthcare systems. Visit our website to learn more about our approach to heart failure management: cardiosense.com #HFWeek2025
-
-
Limited access to specialized cardiology care means that many patients miss out on timely heart failure management. Cardiosense strives to bring technology-driven solutions that can bridge this gap, delivering expert care to underserved communities. Visit our website to learn more about our approach to heart failure management: cardiosense.com #HFWeek2025
-
-
At Cardiosense, we’re committed to working towards a future with better outcomes for patients living with heart failure and the people who care for them. We're developing technology that equips clinicians with actionable insights—enabling early detection for more personalized treatment. Visit our website to learn more about our approach to heart failure management: cardiosense.com #HFWeek2025
-
-
Interview with Liviu Klein discussing the SEISMIC-HF I study results presented at #AHA24 Late-Breaking Science.
CEO non-profit Baim / PERFUSE Research Institute, Harvard Professor, Cardiologist BIDMC, Founder & Chairman WikiDoc.org
Non-invasive measurement of PCWP using AI-based CardioTag device similar to invasive RHC numbers. Data encouraging for widespread hemodynamic-guided remote management of HF pts. Dr. Klein shares results of SEISMIC-HF study https://lnkd.in/eESmKhtE